loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of All Manufacturers & Suppliers for 210824 Licensing, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations listed on PharmaCompass.com

    Client Virtual Booth
    Menu

    Qilu Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 BORTEZOMIB (1)

    filter

    01 QILU PHARM HAINAN (1)

    filter

    01 INJECTABLE;INTRAVENOUS, SUBCUTANEOUS (1)

    filter

    01 3.5MG/VIAL (1)

    filter

    01 USA (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    PDF Supplier PDF
    URL Supplier Web Content
    INJECTABLE;INTRAVENOUS...
    3.5MG/VIAL
    BORTEZOMIB
    USA
    210824
    2022-05-02
    RX
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for CTD TGA MCC DOSSIER APPLICATION 210824

    Looking for CTD TGA MCC DOSSIER APPLICATION 210824 1

    19

    Qilu Pharmaceutical, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

    One of their notable products is BORTEZOMIB, with a corresponding application number 210824 and regulatory information .

    proudly manufactured in the

    approval since 2022-05-02

    Qilu Pharmaceutical's BORTEZOMIB INJECTABLE;INTRAVENOUS, SUBCUTANEOUS, medication with 3.5MG/VIAL of BORTEZOMIB.

    Post Enquiry
    POST ENQUIRY